Tag: Dr Cyrus Karkaria
Lupin receives Health Canada approval for biosimilar Pegfilgrastim
This product will be marketed under the brand name Armlupeg® and manufactured at Lupin’s Biotech facility at Pune, India
Global biotech players repose faith in the India’s biosimilars growth story
The event organized by the International Contract Pharma Association (ICPA) in San Deigo witnessed deliberations on drug discovery services scenario in India
India Unlimited: ICPA event in San Diego on 2nd June to...
Happening on the sidelines of US BIO 2024, the event will see top experts sharing their perspective on how international stakeholders can benefit from outsourcing their requirements to India
India’s biosimilars industry staring at plethora of opportunities
Between now and 2030, biologic products worth US $170 billion will lose patent protection globally, writes Dr Cyrus Karkaria, President – Biotechnology, Lupin Limited
BioVoice eMagazine June 2023 | Issue 6 | Volume 4
This edition tracks the latest scenario in Indian CRO industry and analyzes whether India can become a hotspot for clinical trials. Key highlights include Expert Insights by Dr Cyrus Karkaria, President- Biotechnology, Lupin and Zoya Brar, Founder, CORE Diagnostics.